Recombinant Human EphB4 Fc Chimera Protein, CF

When Recombinant Human EphB4 Fc Chimera Protein (Catalog # 11307-B4) is immobilized at 0.3 µg/mL (100 µL/well), Recombinant Mouse Ephrin-B2 Fc Chimera Protein (496-EB) binds with an ED50 of 0.600-7.20 ng/mL.

2 μg/lane of Recombinant Human EphB4 Fc Chimera Protein (Catalog # 11307-B4) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 95-108 kDa and 190-220 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human EphB4 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human EphB4 Fc Chimera (Catalog # 11307-B4) is immobilized at 0.3 µg/mL (100 µL/well), Recombinant Mouse Ephrin-B2 Fc Chimera (Catalog # 496-EB) binds with an ED₅₀ of 0.600-7.20 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human EphB4 protein
  

  Human EphB4 (Leu16-Arg539) Accession # AAH52804.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: AAH52804.1
• N-terminal Sequence: Leu16
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 58 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 95-108 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human EphB4 Fc Chimera Protein, CF

• EC 2.7.10
• EC 2.7.10.1
• EPH receptor B4
• EphB4
• ephrin type-B receptor 4
• hepatoma transmembrane kinase
• Htk
• HTKephrin receptor EphB4
• Mdk2
• Myk1
• soluble EPHB4 variant 1
• soluble EPHB4 variant 2
• soluble EPHB4 variant 3
• Tyro11
• Tyrosine-protein kinase receptor HTK
• Tyrosine-protein kinase TYRO11

Background

EphB4, also known as Htk, Myk1, Tyro11, and Mdk2, is a member of the Eph receptor tyrosine kinase family and binds Ephrin-B2. The A and B class Eph proteins have a common structural organization (1 - 4). The human EphB4 cDNA encodes a 987 amino acid precursor that includes a 15 amino acid (aa) signal sequence, a 524 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 427 aa cytoplasmic domain (5). The ECD contains an N-terminal globular domain, a cysteine-rich domain, and two fibronectin type III domains. The cytoplasmic domain contains a juxtamembrane motif with two tyrosine residues which are the major autophosphorylation sites, a kinase domain, and a conserved sterile alpha motif (SAM) (5). Activation of kinase activity occurs after membrane-bound or clustered ligand recognition and binding. The ECD of human EphB4 shares 89% aa sequence identity with mouse EphB4 and 42 - 45% aa sequence identity with human EphB1, 2, and 3. EphB4 is expressed preferentially on venous endothelial cells (EC) and inhibits cell-cell adhesion, chemotaxis, and angiogenesis. Opposing effects are induced by signaling through Ephrin-B2 expressed on arterial EC: adhesion, endothelial cell migration, and vessel sprouting (6). EphB4 singaling contributes to new vascularization by guiding venous EC away from Ephrin-B2 expressing EC. Ephrin-B2 signaling induces arterial EC to migrate towards nascent EphB4 expressing vessels (6). The combination of forward signaling through EphB4 and reverse signaling through Ephrin-B2 promotes in vivo mammary tumor growth and tumor-associated angiogenesis (7). EphB4 promotes the differentiation of megakaryocytic and erythroid progenitors but not granulocytic or monocytic progenitors (8, 9).

1. Poliakov, A. et al. (2004) Dev. Cell 7:465.
2. Surawska, H. et al. (2004) Cytokine Growth Factor Rev. 15:419.
3. Pasquale, E.B. (2005) Nat. Rev. Mol. Cell Biol. 6:462.
4. Davy, A. and P. Soriano (2005) Dev. Dyn. 232:1.
5. Bennett, B.D. et al. (1994) J. Biol. Chem. 269:14211.
6. Fuller, T. et al. (2003) J. Cell Sci. 116:2461.
7. Noren, N.K. et al. (2004) Proc. Natl. Acad. Sci. 101:5583.
8. Wang, Z. et al. (2002) Blood 99:2740.
9. Inada, T. et al. (1997) Blood 89:2757.

Bioinformatics

• Uniprot:
  • AAH52804.1(Human)